ArticleBMC nephrology2025
Genetic diagnosis and prenatal diagnosis of patients with cystic kidney disease in Southwest China.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic kidney disease is a heterogeneous chronic kidney disease. It is often difficult to make a definitive diagnosis based on clinical and ultrasound features alone.
methodsA total of 40 families with cystic kidney disease from Southwest China to meet their genetic counseling and prenatal diagnosis needs. To detect renal disease genes, NGS was performed on probands with cystic kidney disease, and candidate variants were validated using Sanger sequencing.
resultsAmong the 40 families, a definitive genetic diagnosis was established in 30 cases (30/40, 75.0%), with seven patients having family members who subsequently underwent prenatal diagnosis based on these molecular findings. We identified a total of 38 variants. According to the criteria of the American College of Medical Genetics and Genomics, 31 variants were classified as pathogenic or likely pathogenic and sevent were classified as uncertain significance. Of the 38 variants, 27 were known and 11 were novel.
conclusionsOur study expands the mutation spectrum for cystic kidney disease gene. Genetic testing is important for clinicians diagnose and guide treatment patients with different types of cystic kidney disease accurately. NGS is a detection technology that can be considered, which is effective in avoiding unexpected misdiagnoses due to clinical overlap among cystic kidney disease. Finally, these results may be useful for the differential diagnosis and genetic counseling of patients with cystic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.